(Q52905228)

9 May 2018

title

Continuation of initial antihypertensive medication after 1 year of therapy. (English)

1 reference

9 May 2018

author name string

Bloom BS

series ordinal

1

1 reference

9 May 2018

publication date

1 July 1998

1 reference

9 May 2018

published in

Clinical Therapeutics

1 reference

9 May 2018

volume

20

1 reference

9 May 2018

issue

4

1 reference

9 May 2018

page(s)

671-681

1 reference

9 May 2018

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

Prevalence of Hypertension in the US Adult Population : Results From the Third National Health and Nutrition Examination Survey, 1988-1991

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

There's good news and not so good news

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

The costs of interrupting antihypertensive drug therapy in a Medicaid population.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

Patterns of antihypertensive use among patients in the US Department of Defense database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

The risk of determining risk with multivariable models

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

Special clinics for hypertension--the role of the hypertension detection--and follow-up programme

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

Benefits of adherence to anti-hypertensive drug therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

The effects of antihypertensive therapy on the quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

Trends in pharmacologic management of hypertension in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

The effect of pharmaceutical benefits managers: is it being evaluated?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2898%2980130-6

7 January 2021

10.1016/S0149-2918(98)80130-6

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018